Perspective Therapeutics Inc (CATX)
1.38
+0.06
(+4.55%)
USD |
NYAM |
May 31, 16:00
1.395
+0.02
(+1.09%)
After-Hours: 20:00
Perspective Therapeutics Research and Development Expense (TTM): 24.91M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 24.91M |
| December 31, 2023 | 20.76M |
| September 30, 2023 | 15.39M |
| June 30, 2023 | 10.47M |
| March 31, 2023 | 5.362M |
| September 30, 2022 | 2.588M |
| June 30, 2022 | 2.582M |
| March 31, 2022 | 2.254M |
| December 31, 2021 | 2.067M |
| September 30, 2021 | 1.817M |
| June 30, 2021 | 1.427M |
| March 31, 2021 | 1.281M |
| December 31, 2020 | 1.213M |
| September 30, 2020 | 1.205M |
| June 30, 2020 | 1.126M |
| March 31, 2020 | 1.145M |
| December 31, 2019 | 1.15M |
| September 30, 2019 | 1.287M |
| June 30, 2019 | 1.474M |
| March 31, 2019 | 1.705M |
| December 31, 2018 | 1.879M |
| September 30, 2018 | 1.805M |
| June 30, 2018 | 1.747M |
| March 31, 2018 | 1.491M |
| December 31, 2017 | 1.345M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.155M |
| June 30, 2017 | 0.965M |
| March 31, 2017 | 0.792M |
| December 31, 2016 | 0.648M |
| September 30, 2016 | 0.556M |
| June 30, 2016 | 0.528M |
| March 31, 2016 | 0.5414M |
| December 31, 2015 | 0.4998M |
| September 30, 2015 | 0.5824M |
| June 30, 2015 | 0.615M |
| March 31, 2015 | 0.6568M |
| December 31, 2014 | 0.669M |
| September 30, 2014 | 0.6984M |
| June 30, 2014 | 0.6688M |
| March 31, 2014 | 0.652M |
| December 31, 2013 | 0.6535M |
| September 30, 2013 | 0.6326M |
| June 30, 2013 | 0.6271M |
| March 31, 2013 | 0.6532M |
| December 31, 2012 | 0.6303M |
| September 30, 2012 | 0.6707M |
| June 30, 2012 | 0.7306M |
| March 31, 2012 | 0.8202M |
| December 31, 2011 | 0.876M |
| September 30, 2011 | 0.702M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.126M
Minimum
Jun 2020
24.91M
Maximum
Mar 2024
5.237M
Average
1.817M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| icad Inc | 5.169M |
| Predictive Oncology Inc | -- |
| Xtant Medical Holdings Inc | 1.689M |
| Asensus Surgical Inc | 34.98M |
| Catheter Precision Inc | 0.272M |